MoonLake Immunotherapeutics (MLTX) vs Seaport Therapeutics, Inc. Common Stock (SPTX)

A side-by-side comparison of MoonLake Immunotherapeutics and Seaport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
MoonLake Immunotherapeutics logo
MLTX
MoonLake Immunotherapeutics
$930M
$11.06HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Seaport Therapeutics, Inc. Common Stock logo
SPTX
Seaport Therapeutics, Inc. Common Stock
$942M
$17.60HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT

Total return — MLTX vs SPTX

growth of $100 · dividends reinvested · last 1y
MLTX -32.0% (-32.0%/yr)SPTX -6.8% (-6.8%/yr)SPTX compounded faster over this window
80100120140Start $100$68$93
MLTX SPTX

MLTX vs SPTX: by the numbers

  • •SPTX is the larger company ($942M vs $930M market cap).

Metrics side by side

Valuation

MetricMLTXSPTX
P/B ratio2.172.23

Profitability

MetricMLTXSPTX
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-61.58%N/A
ROIC-50.77%-36.95%

Growth (annualized)

MetricMLTXSPTX
Total return CAGR (5Y)2.81%N/A

Go deeper

Full MLTX analysisFull SPTX analysisInteractive comparison tool

Dig into the metrics

MoonLake Immunotherapeutics ROESeaport Therapeutics, Inc. Common Stock ROEMoonLake Immunotherapeutics operating marginSeaport Therapeutics, Inc. Common Stock operating marginMoonLake Immunotherapeutics revenue growthSeaport Therapeutics, Inc. Common Stock revenue growthMoonLake Immunotherapeutics free cash flowSeaport Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.